Quick Facts: Deflamon

• Therapeutic Domain: Used to manage and address certain infections caused by susceptible anaerobic bacteria and protozoa.
• Main Uses: Management of infections affecting the abdomen, pelvis, skin, or bones, and in the treatment of certain sexually transmitted infections, such as trichomoniasis.
• Key Benefit: May help to resolve the underlying infectious processes in these indicated conditions.

---

Deflamon (Metronidazole) is an established therapeutic option that may be utilized for the management of various bacterial and protozoal infections in adults. It is indicated for conditions where susceptible anaerobic organisms are present. These uses include addressing infections within the intra-abdominal area, the female genital tract (such as endometritis or pelvic inflammatory disease), and in managing bacterial septicemia.

The medication may also be considered for managing infections affecting the bone and joint structures, the central nervous system, and in specific situations involving skin and soft tissue. In addition to addressing certain bacterial conditions, Deflamon is clinically utilized in the management of protozoal infections like amebiasis (intestinal and extraintestinal forms) and trichomoniasis.

Its function is to assist the body in resolving the infections associated with these conditions.

Regulatory References

1. NIH MedlinePlus guidance on Metronidazole

Eligibility Scope

Category	Regulatory Status
Contraindicated Populations	Individuals with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Contraindicated in patients with Cockayne syndrome due to the risk of fatal liver failure.
Substance Restrictions	Contraindicated for use in patients who have taken Disulfiram within the last 14 days, or who consume alcohol or propylene glycol during treatment and for at least three days after discontinuation.
Condition Restrictions	Use requires caution in patients with severe hepatic impairment; dose reduction is recommended due to slower drug clearance. Caution is also advised for patients with end-stage renal disease and those with a history of blood dyscrasias or seizure disorders.
Age-Related Eligibility	Use is established in adults. Pediatric use is not established for all indications, and newborn infants may have a diminished capacity to eliminate the drug. No specific dose adjustment is mandated for older adults based on age alone, but monitoring is recommended due to potential decline in organ function.
Pregnancy/Lactation	Contraindicated by some authorities for trichomoniasis during the first trimester of pregnancy. Breastfeeding is not recommended during treatment and for a specified time after the final dose.

Official Eligibility Summary

Regulatory documents define who can and cannot use Deflamon by establishing explicit contraindications that prohibit use for specific populations based on severe disease (Cockayne syndrome) or concurrent substance exposure (alcohol/Disulfiram). The official labeling imposes mandatory restrictions on use for populations with impaired organ function, notably severe liver impairment, and advises limitations for certain physiological states, including the first trimester of pregnancy and while breastfeeding, to govern eligibility.

Interactions with other medicines and products

The interaction profile for Deflamon (Metronidazole) defines specific constraints for co-administration with other medicines and substances. Formal prohibitions include combining Metronidazole with Disulfiram; administration is restricted for at least two weeks following Disulfiram use. Consumption of Alcoholic Beverages or products containing Propylene Glycol is also formally contraindicated during therapy and for at least three days after the final dose, as this combination results in a documented disulfiram-like reaction. The use of systemic Metronidazole is also contraindicated in patients with Cockayne Syndrome due to the reported risk of severe hepatotoxicity.

Metronidazole has documented pharmacokinetic and pharmacodynamic interactions that modify the plasma exposure and effects of co-administered agents. The medicine is known to potentiate the anticoagulant effect of Warfarin and related oral coumarin agents, which is documented by a prolongation of prothrombin time (INR). Co-administration may also lead to increased plasma concentrations of medicines such as Lithium and the cytotoxic agent Busulfan. Conversely, agents such as Phenytoin and Phenobarbital can increase the elimination of Metronidazole, resulting in reduced Metronidazole plasma exposure.

In specific patient populations, clearance is altered. Regulatory information notes that patients with severe hepatic impairment (Child-Pugh C) metabolize the medicine slowly, which poses an official risk of accumulation of Metronidazole and its metabolites.

Selective Bio-activation by Anaerobic Pathways

The action of Deflamon is governed by its status as an inactive prodrug, which requires unique biochemical conditions to become effective. It is activated exclusively within susceptible microorganisms—anaerobic bacteria and protozoa—by the low redox potential systems found there, specifically involving enzymes like ferredoxin . This process involves the chemical reduction of the drug's nitro group, yielding highly unstable and potent nitro radical anions. This step establishes the drug's selectivity, which results from the absence of the necessary low-potential reducing machinery in host aerobic cells.

Irreversible Disruption of Microbial Genetic Material

Once generated, these reactive intermediates initiate a definitive toxic cascade. Their primary function is to cause widespread damage to the pathogen's DNA and other nucleic acids. The radicals covalently bind to the genetic structure, resulting in strand breaks and helical distortion. This mechanism immediately and irreparably inhibits nucleic acid synthesis. This molecular effect results in the decisive destruction of the target cell.

Mechanistic Constraints by Oxygen and Resistance

The mechanism is inherently limited by the ambient environment. The presence of oxygen directly competes with the drug for the necessary electrons, inhibiting the formation of the active radical and constraining the drug's efficacy to low-oxygen environments. Furthermore, alterations in the microbial electron transport proteins required for the initial reduction can limit the drug's activation, representing the primary basis for acquired resistance to the drug's mechanism of action.

How to Use Deflamon

This section outlines the standardized administration principles for Deflamon (Metronidazole), focusing strictly on usage patterns and high-level dosing.

---

Deflamon is provided in various formulations to allow for different administration routes, including oral (tablets, capsules, extended-release forms, suspension), intravenous (IV) infusion, and localized topical/vaginal/rectal preparations. For systemic infections, the IV route is often utilized initially, followed by a switch to the oral form. Oral immediate-release forms may be taken with or without food, but extended-release tablets must be taken on an empty stomach (e.g., one hour before or two hours after a meal) and swallowed whole without crushing or chewing.

Standard Dosing and Scheduling

Standard adult systemic dosing for anaerobic infections often involves a weight-based 15 mg/kg loading dose, followed by a maintenance dose of 7.5 mg/kg administered every six hours (q6hr). For certain protozoal infections, regimens can vary from a single 2 g oral dose to 250 mg or 750 mg taken three times daily (TID) for a duration typically between 5 and 10 days. The daily dose for systemic use should generally not exceed 4 g.

Adjustments and Special Conditions

Dosage adjustments are necessary for patients with severe hepatic impairment, where a dosage reduction (e.g., up to 50%) may be required. For patients undergoing hemodialysis, a dose re-administration is specified immediately following the procedure to account for drug removal. If an oral dose is missed, the protocol is to skip the missed dose if it is near the next scheduled time, and to not take two doses simultaneously.

Research Evidence / Overview of Studies for Deflamon (Metronidazole)

Evidence for Use in Protozoal Infections (Trichomoniasis and Amebiasis)

Deflamon (Metronidazole) was studied for its evaluation in conditions involving certain parasites, including Trichomonas vaginalis and Entamoeba histolytica. For trichomoniasis, researchers examined different short-term treatment regimens in Randomized Controlled Trials (RCTs) and systematic reviews, used in research exploring how symptoms change over time. The main outcomes monitored were studied for relating to clinical endpoints and the microbiological clearance rate. Research describes patterns observed in the studies related to parasite clearance following the treatment regimens. For amebiasis, research was evaluated in clinical trials focusing on symptom resolution and confirming the clearance of the parasite. The short treatment period means that long-term follow-up to assess the durability of clearance and patterns of relapse are not fully established.

Evidence for Use in Serious Bacterial Infections (Intra-abdominal Infections)

The use of Metronidazole was studied for its inclusion in regimens for complicated intra-abdominal infections, which are conditions associated with acute or disruptive episodes. Metronidazole was observed in Multicenter Phase 3 studies as a component of a combination antibiotic regimen. The research examined measures related to systemic or functional imbalance, specifically monitoring clinical endpoints and all-cause mortality. Research describes patterns of measured clinical endpoints when Metronidazole was used in combination with other antibacterial agents. Data for certain groups remain insufficient, particularly older adults, and results apply only to the populations studied.

Long-Term Studies and Follow-up Durability

Follow-up durations were limited in many key trials. There is limited information for long-term outcomes regarding the durability of the response for Bacterial Vaginosis (BV) and Periodontitis, both of which are conditions characterized by fluctuating or episodic manifestations. For BV, high rates of recurrence are documented, which suggests that long-term effects are not fully established and more research is ongoing to understand recurrence patterns.

Key Studies & References

1. Metronidazole - StatPearls (General Monograph and Indications)

Common questions about Deflamon (FAQ)

---

Q: Why is Metronidazole contraindicated if I drink alcohol?

Official regulatory documents state that Metronidazole is contraindicated when consumed with alcohol because it can cause a disulfiram-like reaction. This reaction is documented to cause uncomfortable symptoms, including flushing, severe headache, nausea, vomiting, and abdominal cramping.

---

Q: Should I take the oral tablet formulation of Deflamon with food?

The official product information indicates that standard immediate-release tablets or capsules may be taken with or without food. Some official documentation notes that taking the immediate-release tablet with food may help to minimize gastrointestinal discomfort. However, extended-release tablets must be taken on an empty stomach.

---

Q: How long do I need to wait to drink alcohol after stopping Deflamon?

According to the drug's official warnings, the consumption of alcoholic beverages or products containing propylene glycol must be avoided during therapy and for at least three days after taking the final dose of Metronidazole. This restriction is included in the official labeling to help prevent a potentially severe disulfiram-like reaction.

---

Q: How long does a course of Metronidazole treatment typically last for protozoal infections?

Official prescribing information provides treatment regimens for protozoal infections. For adults with protozoal infections like acute intestinal amebiasis, official prescribing information outlines treatment durations that typically range between 5 to 10 days.

---

Q: Can Metronidazole cause liver damage?

Metronidazole has been associated with rare cases of severe liver injury (hepatotoxicity), and it is formally contraindicated in patients with Cockayne syndrome due to the risk of fatal liver failure. For patients with existing liver impairment, official warnings advise that a dosage reduction may be necessary, and they should be monitored for adverse events.

---

Q: Can Deflamon be crushed or chewed?

The official patient information for extended-release tablets explicitly states that these forms must be swallowed whole and should not be broken, crushed, or chewed. Information specific to other tablet or capsule forms can be found in the patient information leaflet.

---

Q: How long after taking Disulfiram can I start Metronidazole?

Regulatory warnings state that Metronidazole is contraindicated for patients who have taken the drug Disulfiram within the last two weeks (14 days). This restriction is included in the official warnings to help avoid a potential severe reaction.

---

Q: Is it safe to use Deflamon while pregnant?

Official regulatory documents note that the use of Metronidazole for trichomoniasis is contraindicated by some authorities during the first trimester of pregnancy. For other indications and trimesters, use is generally reserved for situations where the clinician determines that the potential benefit justifies the potential risk. No adequate and well-controlled studies on pregnant women have been conducted.

---

Q: What should I do with my unused Deflamon medication?

Regulatory guidance advises against flushing unused medication down the toilet or drain. Unused medication is often recommended to be returned to a recognized drug take-back program for safe disposal. If a take-back program is unavailable, certain disposal methods are outlined in government guidelines, such as mixing the medicine with an undesirable substance (e.g., dirt or used coffee grounds), sealing it, and placing it in the household trash.

How to Store and Dispose of Deflamon (Metronidazole)

Storage and disposal requirements for Deflamon are strictly defined by regulatory documents to preserve product quality and ensure safety.

---

Official Storage Conditions

Requirement Type	Condition as per Official Labeling
Temperature	Store at Controlled Room Temperature, typically below 77°F (25°C).
Protection	Keep in the original container, tightly closed, and protected from light.
Freezing/Handling	Do not freeze (especially injection solutions). Keep out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Deflamon must be disposed of in accordance with local regulations for pharmaceutical waste. The official instruction is not to flush the medicine down the toilet or drain, as this prevents the antimicrobial agent from entering the water system. Any single-use containers, such as IV bottles, must have any unused portion discarded immediately.